| Name | Chimmitecan |
| Description | Chimmitecan ((S)-9-Allyl-10-hydroxycamptothecin) is a potent topoisomerase I inhibitor with exceptional in vitro and in vivo activity. |
| In vitro | Chimmitecan was highly cytotoxic (IC50s in the nanomolar range) to a wide variety of tumor cells, including leukemia, lung cancer, gastric cancer, hepatocellular cancer, colon cancer, breast cancer, ovarian cancer, and cervical cancer, and rhabdomyosarcoma cells[1]. |
| In vivo | Chimmitecan (i.v. administration, twice for HCT-116 and thrice for the other tumors per week) caused a dramatic and dose-dependent suppression of tumor growth in all four tumor models. At a dosage of 15 mg/kg, the T/C (%) values were 17.6% (HCT-116), 24.2% (MDA-MB-435), 28.2% (BEL-7402), and 23.0% (A549). when given thrice per week for 2 weeks, chimmitecan (orally administration) inhibited the growth of the A549 xenograft at dosages as low as 4.5 mg/kg, and significant antitumor activity was observed at a dosage of 9 mg/kg[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.05 mg/mL (10 mM)
|
| Keywords | Chimmitecan | 9-Allyl-10-hydroxycamptothecin |
| Inhibitors Related | Berberine chloride | EIDD-1931 | Flumequine | Levofloxacin hydrochloride | Norfloxacin | Prulifloxacin | Enoxacin | Pefloxacin Mesylate | Ciprofloxacin | Ciprofloxacin monohydrochloride | Irinotecan hydrochloride trihydrate | Etoposide |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
